Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects

References

• Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring. Pharmacopsychiatry 2004; 37: 243–265
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb Company and Otsuka America Pharmaceutical Inc. Abilify® (aripiprazole) tablets prescribing information 2006 [online]. Available from URL: http://www.abilify.com.
   Google Scholar
• Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002; 302: 381–389
   PubMed Web of Science ®Google Scholar
• Fujioka T, Teramoto S, Mori T, et al. Novel positive inotropic agents: synthesis and biological activities of 6-(3-amino-2-hydroxypropoxy)-2(1H)-quinolinone derivatives. J Med Chem 1992; 35: 3607–3612
   PubMed Web of Science ®Google Scholar
• Guy W. Clinical global impressions. EDEU assessment manual for psychopharmacology. Revised DHEW Pub (ADM). National Institute for Mental Health, Rockville, MD 1976; 218–222
   Google Scholar
• Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antispsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 2002; 441: 137–140
   PubMed Web of Science ®Google Scholar
• Jordan S, Koprivica V, Dunn R, Tottori K, Kikuchi T, Altar CA. In vivo effects of aripriprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol 2004; 483: 45–53
   PubMed Web of Science ®Google Scholar
• Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63: 763–771
   PubMed Web of Science ®Google Scholar
• Kikuchi T, Tottori K, Uwahodo Y, et al. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 1995; 274: 329–336
   PubMed Web of Science ®Google Scholar
• Kirschbaum KM, Müller MJ, Zernig G, et al. Therapeutic monitoring of aripiprazole by HPLC with column-switching and spectrophotometric detection. Clin Chem 2005; 51: 1718–1721
   PubMed Web of Science ®Google Scholar
• Kubo M, Koue T, Inaba A, et al. Influence of itraconazole co-administration and genotype on the pharmacokinetics of the new antipsychotic aripiprazole. Drug Metab Pharmacokinet 2005; 20: 55–64
   PubMedGoogle Scholar
• Leucht S, Kane JM, Kissling W, Hamann J, Etschel, Engel R. Clinical implications of Brief Psychiatric Rating Scale scores. Br J Psychiatry 2005; 187: 366–377
   PubMed Web of Science ®Google Scholar
• Lingjærde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic–treated patients. Acta Psychiatr Scand Suppl 1987; 334: 1–100
   PubMedGoogle Scholar
• McQuade R, Burris KD, Jordan S, Tottori K, Kurahashi N, Kikuchi T. Aripiprazole: a dopamine-serotonin system stabilizer. Int J Neuropsychopharmacol 2002; 5(Suppl 1)S176
   Google Scholar
• Mizutani T. PM frequencies of major CYPs in Asians and Caucasians. Drug Metab Rev 2003; 35: 99–106
   PubMed Web of Science ®Google Scholar
• Molden E, Lunde H, Lunder N, Refsum H. Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients. Ther Drug Monit 2006; 28: 744–749
   PubMed Web of Science ®Google Scholar
• Perry PJ. Therapeutic drug monitoring of antipsychotics. Psychopharm Bull 2001; 35: 19–29
   PubMedGoogle Scholar
• Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60: 265–271
   PubMedGoogle Scholar
• Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003; 28: 1400–1411
   PubMed Web of Science ®Google Scholar
• Tandon R, Marcus RN, Stock EG, et al. A prospective, multicenter, randomized, parallel–group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA). Schizophr Res 2006; 84: 77–89
   PubMed Web of Science ®Google Scholar
• Ulrich S, Neuhof S, Braun V, Meyer FP. Therapeutic window of serum haloperidol concentration in acute schizophrenia and schizoaffective disorder. Pharmacopsychiatry 1998; 31: 163–169
   PubMed Web of Science ®Google Scholar
• Yang ZY, Xia Y, Xia P, Brossi A, Lee KH. A concise regiospecific synthesis of 8,8-dimethyl-2H, 8H-pyrano[6,5-h]quinolin-2-one and related compounds. Tetrahedron lett 1999; 40: 4505–4506
   Google Scholar